Label: METRONIDAZOLE gel

  • NDC Code(s): 62332-630-45, 62332-630-55, 62332-630-60
  • Packager: Alembic Pharmaceuticals Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated December 22, 2023

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use METRONIDAZOLE GEL safely and effectively. See full prescribing information for METRONIDAZOLE GEL.

    METRONIDAZOLE gel, for topical use.
    Initial U.S. Approval: 1963

    INDICATIONS AND USAGE

    Metronidazole gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea (1)

    DOSAGE AND ADMINISTRATION

    • Not for oral, ophthalmic or intravaginal use. (2)
    • Cleanse treated areas before the application of metronidazole gel. (2)
    • Apply and rub in a thin film of metronidazole gel once daily to affected area(s). (2)
    • Cosmetics may be applied after the application of metronidazole gel. (2)

    DOSAGE FORMS AND STRENGTHS

    Gel, 1%. (3)

    CONTRAINDICATIONS

    Metronidazole gel is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation. (4)

    WARNINGS AND PRECAUTIONS

    • Neurologic Disease: Peripheral neuropathy, characterized by numbness or paresthesia of an extremity has been reported in patients treated with systemic metronidazole. Peripheral neuropathy has been reported with the post approval use of topical metronidazole. The appearance of abnormal neurologic signs should prompt immediate reevaluation of metronidazole gel therapy. (5.1)
    • Blood Dyscrasias: Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of, blood dyscrasia. (5.2)
    • Contact Dermatitis: If dermatitis occurs, patients may need to discontinue use. (5.3)
    • Eye Irritation: Topical metronidazole has been reported to cause tearing of the eyes. Therefore, avoid contact with the eyes. (5.4)

    ADVERSE REACTIONS

    Most common adverse reactions (incidence > 2%) are nasopharyngitis, upper respiratory tract infection, and headache. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Use caution when administering metronidazole gel concomitantly to patients who are receiving anticoagulant treatment. (7)

    USE IN SPECIFIC POPULATIONS

    • Lactation: Breastfeeding not recommended. (8.2)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 12/2023

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Metronidazole gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea.

  • 2 DOSAGE AND ADMINISTRATION

    For topical use only, not for oral, ophthalmic, or intravaginal use.

    Cleanse treated areas before the application of metronidazole gel.

    Apply and rub in a thin film of metronidazole gel once daily to affected area(s).

    Cosmetics may be applied after the application of metronidazole gel.

  • 3 DOSAGE FORMS AND STRENGTHS

    Gel, 1%. Metronidazole gel USP is a clear, colorless to pale yellow gel. Each gram of metronidazole gel USP contains 10 mg (1%) of metronidazole USP.

  • 4 CONTRAINDICATIONS

    Metronidazole gel is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Neurologic Disease

    Peripheral neuropathy, characterized by numbness or paresthesia of an extremity, has been reported in patients treated with systemic metronidazole. peripheral neuropathy has been reported with the post approval use of topical metronidazole. The appearance of abnormal neurologic signs should prompt immediate reevaluation of metronidazole gel therapy. Metronidazole should be administered with caution to patients with central nervous system diseases.

    5.2 Blood Dyscrasias

    Metronidazole is a nitroimidazole; use with care in patients with evidence of, or history of, blood dyscrasia.

    5.3 Contact Dermatitis

    Irritant and allergic contact dermatitis have been reported with metronidazole gel.  If dermatitis occurs, patients may need to discontinue use.

    5.4 Eye Irritation

    Topical metronidazole has been reported to cause tearing of the eyes. Avoid contact with the eyes.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    In a controlled clinical trial, 557 subjects used metronidazole gel, 1% and 189 subjects used the gel vehicle once daily for up to 10 weeks. The following table summarizes selected adverse reactions that occurred at a rate of ≥1%:

    Table 1: Adverse Reactions That Occurred at a Rate of ≥1%
    System Organ Class/Preferred Term
    Metronidazole Gel, 1%
    Vehicle

    N= 557
    N= 189
    Patients with at least one AE 
       Number (%) of Patients
    186 (33.4)
    51 (27.0)
    Infections and infestations
    76 (13.6)
    28 (14.8)
       Bronchitis
    6 (1.1)
    3 (1.6)
       Influenza
    8 (1.4)
    1 (0.5)
       Nasopharyngitis
    17 (3.1)
    8 (4.2)
       Sinusitis
    8 (1.4)
    3 (1.6)
       Upper respiratory tract infection
    14 (2.5)
    4 (2.1)
       Urinary tract infection
    6 (1.1)
    1 (0.5)
       Vaginal mycosis
    1 (0.2)
    2 (1.1)
    Musculoskeletal and connective tissue disorders
    19 (3.4)
    5 (2.6)
       Back pain
    3 (0.5)
    2 (1.1)
    Neoplasms
    4 (0.7)
    2 (1.1)
       Basal cell carcinoma
    1 (0.2)
    2 (1.1)
    Nervous system disorders
    18 (3.2)
    3 (1.6)
       Headache
    12 (2.2)
    1 (0.5)
    Respiratory, thoracic and mediastinal disorders
    22 (3.9)
    5 (2.6)
       Nasal congestion
    6 (1.1)
    3 (1.6)
    Skin and subcutaneous tissue disorders
    36 (6.5)
    12 (6.3)
       Contact dermatitis
    7 (1.3)
    1 (0.5)
       Dry skin
    6 (1.1)
    3 (1.6)
    Vascular disorders
    8 (1.4)
    1 (0.5)
       Hypertension
    6 (1.1)
    1 (0.5)
    Table 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than Baseline
    Metronidazole Gel, 1%
    Vehicle
    Sign/Symptom
    N= 544
    N= 184
    Dryness
    138 (25.4)
    63 (34.2)
      Mild
    93 (17.1)
    41 (22.3)
      Moderate
    42 (7.7)
    20 (10.9)
      Severe
    3 (0.6)
    2 (1.1)
    Scaling
    134 (24.6)
    60 (32.6)
      Mild
    88 (16.2)
    32 (17.4)
      Moderate
    43 (7.9)
    27 (14.7)
      Severe
    3 (0.6)
    1 (0.5)
    Pruritus
    86 (15.8)
    35 (19.0)
      Mild
    53 (9.7)
    21 (11.4)
      Moderate
    27 (5.0)
    13 (7.1)
      Severe
    6 (1.1)
    1 (0.5)
    Stinging/burning
    56 (10.3)
    28 (15.2)
      Mild
    39 (7.2)
    18 (9.8)
      Moderate
    7 (1.3)
    9 (4.9)
      Severe
    10 (1.8)
    1 (0.5)

    The following additional adverse experiences have been reported with the topical use of metronidazole: transient redness, metallic taste, tingling or numbness of extremities, and nausea.

    6.2 Post marketing Experience

    The following adverse reaction has been identified during post-approval use of topical metronidazole. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

    Nervous System Disorders: Peripheral neuropathy [see Warnings and Precautions (5.1)]

  • 7 DRUG INTERACTIONS

    Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Drug interactions should be kept in mind when metronidazole gel is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Available data have not established an association with metronidazole use during pregnancy and major birth defects, miscarriage or other adverse maternal or fetal outcomes. No fetotoxicity was observed after oral administration of metronidazole in pregnant rats or mice. The available data do not allow the calculation of relevant comparisons between the systemic exposures of metronidazole observed in animal studies to the systemic exposures that would be expected in humans after topical use of metronidazole gel.

    The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    8.2 Lactation

    Risk Summary

    It is not known whether metronidazole is present in human milk after topical administration. Published literature reports the presence of metronidazole in human milk after oral administration. There are reports of diarrhea and candida infection in breastfed infants of mothers receiving oral treatment with metronidazole. There are no data on the effects of metronidazole on milk production. Because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with metronidazole gel.

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    8.5 Geriatric Use

    Sixty-six subjects aged 65 years and older were treated with metronidazole gel, 1% in the clinical study. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

  • 11 DESCRIPTION

    Metronidazole gel USP, 1% contains metronidazole, USP. It is intended for topical use. Chemically, metronidazole is 2-methyl-5-nitro-1 H-imidazole-1-ethanol. The molecular formula for metronidazole is C6H9N3O3. It has the following structural formula:

    Image

    Metronidazole has a molecular weight of 171.16. It is a white to pale yellow crystalline powder. It is slightly soluble in alcohol and has solubility in water of 10 mg/mL at 20˚C. Metronidazole belongs to the nitroimidazole class of compounds.

    Metronidazole gel USP, 1% is a clear, colorless to pale yellow, aqueous gel; each gram contains 10 mg of metronidazole in a base of betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of action of metronidazole in the treatment of rosacea is unknown.

    12.2 Pharmacodynamics

    The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown.

    Cardiac Electrophysiology: The effect of metronidazole gel on the QTc interval has not been adequately characterized.

    12.3 Pharmacokinetics

    Topical administration of a one-gram dose of metronidazole gel to the face of 13 subjects with moderate to severe rosacea once daily for 7 days resulted in a mean ± SD Cmax of metronidazole of 32 ± 9 ng/mL. The mean ± SD AUC(0 to 24) was 595 ± 154 ng*hr/mL. The mean Cmax and AUC(0 to 24) are less than 1% of the value reported for a single 250 mg oral dose of metronidazole. The time to maximum plasma concentration (Tmax) was 6 to 10 hours after topical application.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Metronidazole has shown evidence of carcinogenic activity in studies involving chronic oral administration in mice and rats, but not in studies involving hamsters.

    In several long-term studies in mice, oral doses of approximately 225 mg/m2/day or greater were associated with an increase in pulmonary tumors and lymphomas. Several long-term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses >885 mg/m2/day.

    Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood lymphocytes was reported in patients with Crohn's disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating lymphocytes was observed in patients with Crohn's disease treated with the drug for 8 months.

  • 14 CLINICAL STUDIES

    In a randomized, vehicle-controlled trial, 746 subjects with rosacea were treated with metronidazole gel,1% or vehicle once daily for 10 weeks. Most subjects had a disease severity score of 3 ("moderate") on the 5-point Investigator Global Assessment (IGA) scale, with 8 to 50 inflammatory lesions and no more than two nodules at baseline. The co-primary efficacy endpoints were the percent reduction in inflammatory lesion counts and percentage of subjects with success on IGA, defined as an IGA score of 0 ("clear") or 1 ("almost clear") at Week 10. 

    The efficacy results are shown in the following table:

    Table 3: Inflammatory Lesion Counts and Global Scores in a Clinical Trial of Rosacea
    Metronidazole Gel, 1%
    Vehicle
    N
    Results N (%)
    N
    Results N (%)
    Inflammatory lesions
    557
    189
    Baseline, mean count
    18.3
    18.4
    Week-10, mean count
    8.9
    12.8
    Reduction
    9.4 (50.7)
    5.6 (32.6)
    Investigator Global Assessment
    557
    189
    Subject clear or almost clear
    214 (38.42)
    52 (27.51)
    Subject with no change
    159 (28.5)
    77 (40.7)

    Subjects treated with metronidazole gel, 1% experienced a mean reduction of 9.4 inflammatory lesions in the Week-10 LOCF group, compared to a reduction of 5.6 for those treated with vehicle, or a difference in means of 3.8 lesions.

    The contribution to efficacy of individual components of the vehicle has not been established.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How supplied

     Metronidazole gel USP, 1% is a clear, colorless to pale yellow in color, and supplied as follows:

    45 gram tube- NDC 62332-630-45

    60 gram tube- NDC 62332-630-60

    55 gram pump- NDC 62332-630-55

    16.2 Storage and handling

    Storage Conditions: Store at 20˚ to 25˚C (68˚ to 77˚F); excursions permitted between 15˚ to 30˚C (59˚ to 86˚F) [see USP controlled room temperature].

  • 17 PATIENT COUNSELING INFORMATION

    Advise the Patient to read the FDA-approved patient labeling (Patient Information).

    Administration Instructions

    Use as directed. Avoid contact with the eyes.

    Cleanse treated areas before the application of metronidazole gel.

    Advise patients to report any adverse reaction to their healthcare providers.

    Lactation

    Advise women not to breastfeed during treatment with metronidazole gel [see Use in Specific Populations (8.2)].  

    Rx Only

    Manufactured for:

    Alembic Pharmaceuticals, Inc.

    Bedminster, NJ 07921, USA

    Manufactured by:

    Alembic Pharmaceuticals Limited

    (Derma Division),

    Karakhadi, Vadodara 391450, India.

    Mfg. License No.: G/25/2216

  • PATIENT INFORMATION

                                                                 PATIENT INFORMATION 
                                                           Metronidazole (MET-roe-NYE-da-zole) Gel, USP 1%
    Important: Metronidazole gel is for use on the skin only (topical use). Do not use metronidazole gel in your mouth, eyes, or vagina. 
    What is Metronidazole gel ?
    Metronidazole gel is a prescription medicine used on the skin (topical) to treat pimples and bumps (inflammatory lesions) caused by a condition called rosacea.
    It is not known if metronidazole gel is safe and effective in children.            
    Do not use Metronidazole gel if you are allergic to metronidazole or any of the ingredients in metronidazole gel. See the end of this leaflet for a complete list of ingredients in metronidazole gel. 
    Before using Metronidazole gel , tell your healthcare provider about all your medical conditions, including if you:
    • have tingling or numbness in your hands or feet 
    • have or have had a blood disorder or disease 
    • are pregnant or plan to become pregnant. It is not known if metronidazole gel will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if metronidazole gel passes into your breast milk. Do not breastfeed during treatment with metronidazole gel. Talk to your healthcare provider about the best way to feed your baby during treatment with metronidazole gel.
    Tell your healthcare provider about all of the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. 
    How should I use Metronidazole gel ?
    • Use metronidazole gel exactly as your healthcare provider tells you to. 
    • Cleanse the treated area before applying metronidazole gel.
    • Apply and rub in a thin film of metronidazole gel 1 time a day to the affected area(s).
    • You can apply cosmetics after applying metronidazole gel.
    • Avoid contact of metronidazole gel with your eyes.
    What are the possible side effects of Metronidazole gel ?
    Metronidazole gel may cause serious side effects, including:
    • Peripheral neuropathy. Tingling, burning, pain or numbness in the hands or feet (peripheral neuropathy) have happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tingling, burning, pain or numbness in your hands or feet during treatment with metronidazole gel.
    • Skin reactions, including allergic reactions. Tell your healthcare provider if you develop any skin reactions, including rash, itching, redness, swelling, or blisters during treatment with metronidazole gel. 
    • Eye irritation. Tearing from eye irritation has happened in people treated with metronidazole used on the skin. Tell your healthcare provider if you experience tearing, redness or discomfort of the eyes during treatment with metronidazole gel. 
    The most common side effects of Metronidazole gel include:
    • sore throat and nasal congestion
    • upper respiratory tract infections
    • headache
    Tell your healthcare provider if you get any side effects during treatment with metronidazole gel. 
    These are not all of the possible side effects of metronidazole gel.
    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. 
    You may also report side effects to Alembic Pharmaceuticals, Inc. at 1-866-210-9797.
    How should I store Metronidazole gel ?
    • Store metronidazole gel at room temperature between 68°F to 77°F (20°C to 25°C).
    Keep Metronidazole gel and all medicines out of the reach of children.
    General information about the safe and effective use of Metronidazole gel .
    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use metronidazole gel for a condition for which it was not prescribed. Do not give metronidazole gel to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about metronidazole gel that is written for health professionals.
    What are the ingredients in Metronidazole gel ?
    Active ingredient: metronidazole
    Inactive ingredients: betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water
    Manufactured for:
    Alembic Pharmaceuticals, Inc.
    Bedminster, NJ 07921, USA
    Manufactured by:
    Alembic Pharmaceuticals Limited
    (Derma Division),
    Karakhadi, Vadodara 391450, India.
    Mfg. License No.: G/25/2216
    For more information, call Alembic Pharmaceuticals, Inc. at 1-866-210-9797.

    This Patient information has been approved by the U.S. Food and Drug Administration                                        12/2023

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Metronidazole Gel USP, 1%

    For Topical Use Only

    NDC 62332-630-60

    Rx Only

    60 grams

    For topical use only.

    Not for oral, ophthalmic or intravaginal use.

    Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.

    Usual dosage: Apply a thin film once a day to affected areas.  See prescribing information for complete instructions.

    Each gram contains: 10 mg (1%) metronidazole USP, as active ingredient in a gel base consisting of betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben, and purified water.

    Manufactured for:

    Alembic Pharmaceuticals, Inc.

    Bedminster, NJ 07921, USA

    Manufactured by:

    Alembic Pharmaceuticals Limited

    (Derma Division),

    Karakhadi, Vadodara 391450, India.

    Mfg. License No.: G/25/2216

    label
    carton label
  • INGREDIENTS AND APPEARANCE
    METRONIDAZOLE 
    metronidazole gel
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:62332-630
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E) METRONIDAZOLE10 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    BETADEX (UNII: JV039JZZ3A)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    NIACINAMIDE (UNII: 25X51I8RD4)  
    PHENOXYETHANOL (UNII: HIE492ZZ3T)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    WATER (UNII: 059QF0KO0R)  
    HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) (UNII: ZYD53NBL45)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:62332-630-451 in 1 CARTON09/06/2021
    145 g in 1 TUBE; Type 0: Not a Combination Product
    2NDC:62332-630-601 in 1 CARTON09/06/2021
    260 g in 1 TUBE; Type 0: Not a Combination Product
    3NDC:62332-630-551 in 1 CARTON09/06/2021
    355 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21264609/06/2021
    Labeler - Alembic Pharmaceuticals Inc. (079288842)
    Registrant - Alembic Pharmaceuticals Limited (650574663)
    Establishment
    NameAddressID/FEIBusiness Operations
    Alembic Pharmaceuticals Limited871411532MANUFACTURE(62332-630) , ANALYSIS(62332-630)